(Q34526378)

2 August 2017

1 reference

title

In vivo purging and relapse prevention following ASCT. (English)

1 reference

2 August 2017

1 reference

Gisselbrecht C

1

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 February 2002

1 reference

Bone Marrow Transplantation

2 August 2017

published in

1 reference

2 August 2017

volume

29 Suppl 1

1 reference

2 August 2017

page(s)

S5-9

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1703295

2 August 2017

exact match

0 references

cites work

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703295

High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703295

Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation--results of a retrospective analysis on 120 patients autografted in a single institution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703295

Purging peripheral blood progenitor cell grafts from lymphoma cells: quantitative comparison of immunomagnetic CD34+ selection systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703295

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703295

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703295

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703295

Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703295

Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703295

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703295

Immunomagnetic bone marrow (BM) and peripheral blood progenitor cell (PBPC) purging in follicular lymphoma (FL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703295

The CUP trial: a randomized study analyzing the efficacy of high dose therapy and purging in low-grade non-Hodgkin's lymphoma (NHL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703295

A quantitative study of peripheral blood stem cell contamination in diffuse large-cell non-Hodgkin's lymphoma: one-half of patients significantly mobilize malignant cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703295

7 January 2021

Comparative Preclinical Study of Three Bone Marrow Purging Methods Using PCR Evaluation of Residual t(14;18) Lymphoma Cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703295

7 January 2021

Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703295

7 January 2021

Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703295

7 January 2021

In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703295

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1703295

1 reference

Dimensions Publication ID

2 August 2017

1026933854

0 references

1 reference